AXV 301
Alternative Names: AXV-301Latest Information Update: 27 Jun 2023
At a glance
- Originator Axovia Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ciliopathies
Most Recent Events
- 06 Apr 2023 Axovia Therapeutics plans a First in Human trial for Ciliopathies in 2025 (Axovia Therapeutics pipeline, April 2023)
- 06 Apr 2023 Preclinical trials in Ciliopathies in United Kingdom (parenteral) before April 2023 (Axovia Therapeutics, pipeline April 2023)